

W/D

GAU 1643

#8 [Signature]  
7/29/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Li How Chen and Harry Meade

Serial No.: 09/175,683

Filing Date: October 20, 1998

Docket Number: 107.637.121B

Title: NOVEL MODIFIED NUCLEIC ACID SEQUENCES  
AND METHODS FOR INCREASING mRNA LEVELS AND  
PROTEIN EXPRESSION IN CELL SYSTEMS

MAR 12 1999  
MATRIX CUSTOMER  
SERVICE CENTER

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT  
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID  
SEQUENCE DISCLOSURES**

In Response to the Notice to Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures, mailed on  
November 13, 1998 for the above-identified patent application, applicants herewith submit  
the following:

1. Statement Under 37 C.F.R. §1.821(f);
2. Diskette Containing Computer Readable Format of Sequence Listing;
3. Paper copy of Sequence Listing (3 pages) identical to Computer Readable  
Format of Sequence Listing on the Diskette;
4. Copy of Notice To Comply with Requirements for Patent Applications  
Containing Nucleotide Sequence and/or Amino Acid Sequence  
Disclosures mailed November 13, 1998; and
5. Return Postcard.

U.S.S.N. 09/175,683


Page -2-

No additional costs are believed to be due in connection with the filing of this Response. However, please charge any necessary fees to our Deposit Account No. 08-0219.

If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,

HALE AND DORR LLP



Simona A. Levi-Minzi, Ph.D.

Registration No. P-43,750

Attorney for Applicants

60 State Street  
Boston, MA 02109  
Tel: (617) 526-6000  
Fax: (617) 526-5000

Date: March 4, 1999

CERTIFICATE OF MAILING (37 C.F.R. § 1.8(a))

*I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to BOX SEQUENCE, Assistant Commissioner for Patents, Washington, DC 20231 on the date indicated below.*

Date: 3/4/99

By   
Angelo J. Mignatelli

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO./TITLE
--------------------	---------------------	-----------------------	---------------------------

001121001 10/24/98 CHEN

107.637.121

0242/1113

HALE AND DORR  
60 STATE STREET  
BOSTON MA 02109

NOT ASSIGNED

1643

DATE MAILED:

11/13/98

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER: \_\_\_\_\_

**APPLICANT MUST PROVIDE:**

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☐ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

**FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:**

- ☐ For Rules Interpretation, call (703) 308-1123.
- ☐ For CRF submission help, call (703) 308-4212.
- ☐ For PatentIn software help, call (703) 308-6856.